According to data from Deloitte Recap LLC, cancer drugs are the most popular compounds to partner, making up 33 percent of all deals in 2012. The popularity has increased from the five years prior to that when oncology drugs made up 24 percent of the licensing deals. In the first quarter of 2013, the fraction held steady at one third of all deals. Read More